In human CRC patients, tumoral tissue shows a significant decrease in the percentage of CCR9+ CD8+ T lymphocytes compared to non-tumoral tissue, suggesting that they may be biologically relevant for the anti-tumoral immune response [29]. This evidence concerns the gene CCR9 and colorectal carcinoma.